摘要：抗凝药物在连续性血液净化(CBP)中起着重要作用，目前常用的传统抗凝药物包括肝素、低分子肝素、枸橼酸等，这些药物都有相应的并发症及禁忌症。ICU中，当面对高出血风险患者，尤其是同时合并肝功能不全、高乳酸血症等情况时，上述抗凝药物或均存在局限性，而甲磺酸萘莫司他(Nafamostat Mesilate)具有安全、有效等特点，可作为高出血风险患者进行连续性血液净化的抗凝首选。但是，萘莫司他使用的监测指标及其优势、局限等仍需更多临床试验验证。本文主要总结高出血风险患者使用萘莫司他作为连续性血液净化治疗抗凝药物的应用，为临床决策等方面提供参考依据。

    关键词：甲磺酸萘莫司他；抗凝；高出血风险；连续性血液净化

    中图分类号：R459.5" " " " " " " " " " " " " " " " "文献标识码：A" " " " " " " " " " " " " " " " "DOI：10.3969/j.issn.1006-1959.2025.04.035

    文章编号：1006-1959(2025)04-0182-06

    Application of Nafamostat Mesylate in Continuous Blood Purification

    for ICU Patients with High Bleeding Risk

    REN Yanwen1， XIANG Shulin2

    (1.Graduate School of Youjiang Medical University for Nationalities， Baise 533000， Guangxi， China;

    2.Department of Critical Care Medicine of the People's Hospital of Guangxi Zhuang Autonomous Region/

    Guangxi Academy of Medical Sciences， Nanning 530021， Guangxi， China)

    Abstract： Anticoagulant drugs play an important role in continuous blood purification (CBP). At present ......